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Objectives. This siady was designed to compare the acute 
systemic and coronnry hemcdynamtc eEects of high doses of 
iairavenctus diltiazem in patienls with normal wrsus impaired letl 
ventricular function, investigate the safety of this drug and 
cuntpare i!s anti-iehemic paiealial in these two patient grw~s 
during paeingJnduced stress. 
Background, Beeawe coronary hemadynamic effects and ntl: 
ative inotrqk properties of dittiazem are dose related, high dose 
intravenous diltiazem may improve anti-ischemic efficacy bat may 
not be tolerated ia palients with impaired eardisc function. 
Methods. High dose intravenous diitiazem, 0.4 mglkg for 5 min 
foltnwed by 0.4 mgikg for IO mitt, was administered to 23 
nurrnotwoivc patients wilh cornnary artery disease, 11 (group A) 
with norntnl and 12 (group B) with impaired ventricular functinn 
(ejection ftwttnn <45%) daring two identical atrial pacing stress 
tests perfcnmed 30 min before tpaclng test 1) and immediately 
after diltiazem (pacing lest II). 
Resaks. Dilliseem was well tolerated espite hi@ peak plmma 
levek, 869 t 152 mertgmup A) and 926 _c 169 t$i!ertgmup 
B). It twtlted in immedtatc but shnilnr reductions in systemic 
resistance fmn 1321 + 136 (enntrol value) to %3 t El3 
dynawem-5 (group A) and from 1,267 f 106 to 865 + 58 
dynevs-cm-s @aup Et) and in mean arterial pressure rmm 107 & 
3to93*4mmHg~gmupA)and~romIO3~4to86*4mmmHg 
(graup IS), at 5 mta afler dilthzem (all p < 0.05 YS. cantml value). 
Diltiazem improved strnke oatpat kern 36 t 3 (centrot value) to 
The antiauginal efficacy of dikiazem administered orally 
improves with inciemcms in dose (1.2). Also. high dose 
intravenous diltiazem (that is, an infusion rate of 56 &nint 
results in well defimxt anti-ischeaic effects (3, the latter 
being variable when lower doses (18 to 35 &mint are 
administered (4-7). Moreover. in humans. imurovements in 
coronary flow’appear to be dose dependent as’well t3.8-13). 
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16 * J mikat per n? in group Band kom 44 rk 4 (ceatrd value) 
to 49 2 5 mUbeat per m* in group A, an effmt that w= 
~ipnificanlly greatersntt more pmkngedtn grnupBthan tu gtwa 
A. Although neither heart rate nor eontrnetility was a&ted in 
either group, left ventrktdsr end~ttimtetic pressure imreased in 
group A (9 ? 2 mm Hg to 12 + 1 mm Hg, p < 0.05) but not in 
group 8. Despite shnitnr reductions in euronary redstance and 
impror.emrnk5 in coronary tktu. diltbzem mnsictenliy r&wed 
myecardial oxygen extraction. but only in group B. Ake, the 
nnti.kchemic etfects uf dittinaetn were mere pmntmneea in group 
6. Guring pasing tmt II, myncardird lactate xtrnction wxtna#zed 
in group B (7 + 5% vs. -6 * 12% [paclngtesttj) butnottngmnp 
A, contractility indexes imprnved mare and the increase in Ml 
ventrieutar filling pressure was reduced to n greater extent in 
grnnp 6. Mereaver. the kcberniu-induced iacrease in arterhd 
pressures, observed tn bath gbxtps during pacing test I, was 
prevented in grwp B hut recurred in grnup A during pacing test 
II. 
Conchsions. High dose intrnrenws diltiazem k wetI tolerated, 
augments caronq t?w and improves Ml venbicular pump 
Iunction, particularly in patients with preexistiig ventrkular 
dysfunction. As its anti-ixhamic effects also aptwr more pro- 
nounced in the latter group, high dose dtltlazem may be pa&a- 
bly useful when ventricular betion is depressed, for exampk, 
duritlg praloaged txhemia at rest. 
(I Am Co11 Cardiol1993~1:769-201 
Several studies have shown that diltiazem may limit 
myocardial injury during prolonged psriods of ischemia or 
the acute phase ofmyocardial infarctha (14,15). Moreover. 
animal experiments indicate that dwing infarction and 
thrombaiytic therapy diltiazem results in further salvage of 
myocardial tissue, in addition to the effect of thrombolysis 
(16). Thus. it may be useful in similar conditions in humans, 
provided it is given intravenously and in a sufficiently high 
dose to permit profit from its coronary vasodilator effect. 
However, in clinical situations. such as infarction or pro- 
longed ischemia at rest, where left ventricular function is 
commonly reduced, high doses may be contraindicated 
because of the intrinsic negative inotropic properties of 
diltiazem. which are dose related in vitro (17,18). In patients 
with chronic heart failure. a relatively low intravenous dose 
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of diltiazem is well tolerated (14). Conversely. in patients 
with normal ventricular function, high intravenous doses do 
not negatively affect myocardisl contractility or left ventric- 
ular pump function (3). However, no data are avar;able on 
the xute bemodynamic effcc!s of :he latter dose regimen in 
patients with diminished left ventricular function withort 
sympioms of heart failure. Moreover, the anti-ischemic 
efficacy of high dose intravenous diltiazcm in such patients 
has not been established. The present study compares the 
acute systemic and coronary hemodynamic effects of high 
doses of intravenous diltiazem in patients with normal ver- 
sus impaired left ventricular function, investigates its safety 
and compares its anti-ischemic potential in these two patient 
groups during pacing-induced stress. 
Methods 
Study patients. After approval of the study protocol by 
the Human Studies Committee of the Zuideniekenhuis and 
after informed consent was obtained, 23 patients partici- 
oated in this studv: 21 men and 2 women (mean see 54 “ears. . 
range 41 to 68). All underwent cardiac cathete&ation be- 
cause of stable, exercise-induced angina with objective signs 
of ischemia during exercise testing or a documented old 
myocardial infarction, or both. Patients with systemic hy- 
pertension, valvular disease, a recent myocardial infarction 
(<2 months earlier), conduction disturbances or signs of 
congestive heart failure were not included in the study. Also, 
patients with unstable angina or angina at rest or e!ectrocar- 
diographic (ECG) changes suggestive ofvariant angina were 
excluded. Withdrawal of all cardiac therapy was completed 
by 48 to 72 h before the study with the exception of 
short-acting nitroglycerin, which wras permitted up to 6 h 
before the investigation. Coumarin derivatives were with- 
held 72 h before the study and the administration of anti- 
platelet drugs such as aspirin was stopped 210 days before 
the investigation. Patients could participate only if coronary 
angiography preceding the study showed the presence of a 
~70% diameter reduction in either the left anterior descend- 
ing artery, the proximal IeR circumflex artery or a proximal 
margina branch of the left coronary artery. The severity of 
the coronary artery lesion was determined after catheteriza- 
tion by visual analysis and, in case of doubt, by caliper- 
assisted determination. Moreover, on the basis of radio- 
nuclide angiography performed before the study, patients 
were classified into those with normal left ventricutar func- 
tion (ejection fraction >45%, group A, n = II) and those 
with an impaired function (group B. n = 12). Clinical 
characteristics and angiographic data nrc given in Table I. 
Both groups were comparable with respect to gender, age, 
exercise-inducible &hernia and number ofdiseased vessels. 
In group B previous infarcts were more frequent and left 
ventricular end-diastolic volume was significantly greater 
than in group A. By design, left ventricular ejection fraction 
was higher in group A (58 + 2%) than in group B (35 * 2%. 
p < 0.05). 
Table 1. Clinical Characteristics and An&graphic Data 
Gmup A: WI Group B: Lefl 
Ventncut Ejcctios Vealricular Ejechn 
Fraction >45% Fraction +456 
Patien,s WI= II, (II = 121 
A&e (~0 51 f 5 (range 39 to 671 51 t 3 ,range 40 to 66) 
Mlnlwomen WI 1111 
Fwiour inhrct 
AlWli0r 4 7 
inferior 3 7 
Exercise-induced angina 9 IO 
Positive 131 ergometry 8 7 
Coronary angiqsaphy 
(>709b stenosis) 
I-VD 4 5 
I-V0 3 2 
WD 4 5 
LV ejectmn lrdcfion t%) 58 = 2 35 z 1’ 
LV enddiartolic volume 59 2 5.4 97 t w 
tmWm4 
‘p < O.QS group A VFIDUI areup B. Valuer are expressed as mean value * 
SEM or numkr of patients. LV = left ventricular; VD = vessel discax. 
Cathetedzatfon procettures. Patients underwent cardiac 
catheterization without premeditation in the morning after 
an overnight fast. First, left and right coronary angiography 
was performed with nonionic contrast material (iopamidol) 
with use of the Seldinger technique. Next, a 7F therntodilu- 
tion pacing cathcic: (Wilton Webster) was inserted into the 
coronary sinus through a br+lchiat vein, so that the proximal 
thermistor was 22 cm beyond the orifice of the coronary 
sinus. the catheter position was stable and bhtod could be 
drawn quickly enough to allow far a rapid sequence of blood 
samples. The absence of atrial reflux was confirmed by a 
bolus injectioit of saline solution at room temperature into 
the right atrium. A 7F balloon-tipped, triple-lumen thermodi- 
lntion catheter was positioned in a pulmonary artery through 
a Desilet system in the right femoral vein. Care was taken 
that the catheter tip was stable without baseline drift on the 
thermoditution signal. Finally, a 7F or SF Milk or Sentron 
pigtail angiographic microttuutometer catheter was intro- 
duced into the left ventricle through a Desilet introducer 
system into a femoral artery. The side arm of thb system 
was used to rr_ord arterial pressures. The position of the 
catheters was recorded on video disk to allow rechecking of 
their respective positions during the study. 
Measurements. Hemodynamic measurements included 
mean and phasic systemic arterial, pulmonary artery and 
right atrial pressures; left ventricular peak systolic, mean 
and end-diastolic pressures; left ventricular pressure-derived 
contractility indexes (left ventricular peak first derivative of 
left ventricular pressure [dP/dtl, VceQO[dP/dtlP at P = 40 mm 
Hgl and Vmax IdPldtlp extrapolated to F i 0 nun Hg total 
pressure]); therrnodilution cardiac output (in triplicate), and 
coronary sinus blood flow. All fluid-filled catheters were 
calibrated by using Bentley transducers with a zero refer- 
ence level set at midchest. The micromanometer pressures 
were balanced to zero and supenmposed on the conven- 
tional pressure tracings. After appropriate calibration. all 
pressure and Aow signals and left ventricular dp’di uere 
recorded on paper at different paper speeds. for example. 25. 
SO and IO0 mm/s. using a CGR IUCD catheter Idboratory 
system. Cardiac output was measured on line by a Mennen 
catheterization laboratory computer system. This system 
also allows for the on-line determination of nil pressures and 
pressure-derived contraclility indexes measured over I? ID 
I.5 consecutive beats. Coronary sinus blood Row was deter- 
mined during a continuous 30-s infusion of 30 to 35 ml of 5% 
glucose at room temperature. Both the mean and phasic flow 
were recorded. Calculations were mnde from the mean RW 
curve according to the formula: Coronary sinus bloud flow 
(ml/min) = V, x [(Th - Ti)/(Tb - Tcs) - I] x 1.08. ehcre 
V, is the rate of the injectate (mUmin\. Tb is ihc blood 
temperature before injection, Ti is the temperature of !he 
injectate and Tcs is the temperature of the mixture of 
coronary sinus blood and injectate. At the end of the study. 
the pressure curves from the femoral artery were compared 
with a simultaneous recording from the aortic root by the 
micromanometer catheter to compensate for any dilference 
between proximal and distal arterial pressures. 
Mctaholiiand ECG measurements. Arterial and coronary 
venous blood was sampled simultaneously IO determine 
oxygen and lactate. Oxygen saturation values were mew- 
sured wii an American Optical Oxymeter. For the determi- 
nation of lactate, I ml oi whole bload was collected and 
immediately deproteinized in I-ml ice,cold 8% perchloric 
acid, vortexed and kept on ice until further assay. The 
procedures for lactate determination and ihe SD of the assay 
inourtabomtory have been previously published (20). Henrt 
rate and ST segment changes were determined from 
iGOmm/s recordings of ECG i-ads 1. II and V,. The ST 
segment was measured in S consecutive beats. 0.08 s after 
the J point, with a calibrated magnifying Lens. Plasma 
dihiazem levels were determined by high performance liquid 
chromatography analysis. 
Calcolatiins. Coronary vascular resistance (mm Hdml 
per min) was calculated as the difference between lnean 
arterial pressure (mm Hg) and left ventricular mean diastolic 
pressure (mm Hg) divided by coronary sinus blood Row 
(m!/min). Systemic vascular resistance Idynesvcm~‘) was 
derived as (mean arterial pressure [mm Hgl - mean right 
arterial pressure [mm Hgl) x SO/cardiac output (litersimin). 
Fipure I. Schematic representation of study protocol. Diltiazem is 
sdminnrered over IS min. 30 min afterandjust before two identical 
arrial pscmg stress testy (APST I and APST II. respectivelyI. 
Hemodynamic and metabolic variabtes are evaluated a predeter- 
mined intervals designated by ehsed arrows. In addition. cardiac 
oulpul I\ marored before and 5 and 15 min alter the onset of 
dhrcm adminislmtion (qen awows). b = beaL5: C = conlrol: 
HR - kran rale, MAX = maximal pacing raes. 
Stroke work index lemlrn?) was calculated as stroke index 
lmlibeat per m’l x (mean &erial pressure [mm Hgl - left 
\,cntriculnr end diastolic pressure [mm Hgl) x 0.0136. Myo- 
c;lrdiat oaygcn entr-ction (ml OJml) was calculated as 
arterial oxygen content (ml Cl,lml) - coronary venons axy- 
fen content (ml OJml); nd myocardiai oxygen consumption 
(mllminl as the product of myocardial oxygen e:.rraction (ml 
Ol!ml) and coronary blood flow (mlimin). Percent myocar- 
dial lactate entraction was calculated as lo(l x (arterial 
lactale cunlenl Immollliler] - coronary venous lactate con- 
tent [mmol!liter])inrtctial lactate content [mm&liter]). My* 
cardial lactate uptake (mmolimin) was determined by multi- 
plying the difference in arterial and coronary venous lactate 
content immol/ml) with coronary blood flow (mUmin). 
Study prntoc~I (Fig. I). At least 40 min after the last 
coronmy angiogmm and 29 min after inmrumentatiou. mul- 
tiple comrol measurements of all variables. except cardiac 
output. were performed to ensure stable baseline vah~es. An 
atria! pacing stress test (pacing test B then followed. during 
which heart rate was elevated by 10 beats0 min until 
moderate to .evey angina1 pain or atrioventricular block 
occurred or a maximal hean rate of 170 beatsimin was 
reached. Repeated determinations of all hemodynamic and 
metabolic variables were performed at fixed intervals during 
pacing an?l during maximal pacing rates followed by mea- 
suremen!a at I5 s and 1.2 and 5 min after pacing. Coronaq 
Row was measured during the last 30 s of pacing and during 
the ?-min period after pacing. 
A 30-min stabilization period was allowed after pacing 
test I. followed by multiple control determinations ofhemo- 
dynamic and me?abolic variables. Next. diltiazem was ad- 
ministered intravenously (0.4 mglkg during 5 min followed 
by 0.4 mg/kg duting IO min) and measurements were re- 
peated at I, 3. 5. 10 and I5 min after the onset of drug 
administration. Cardiac outpttt was determined a~ baseline 
and at 5 and 15 min of diltiazem administration. Immediately 
after diltiazem infusion, a second arrial pacing sN.s test 
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Table 2. Syslcmic Hemodynamic Changes During: Dilliazem Administration in Patients With Normal Versus Impaired LeR 
Ventric~~lnr Rmcrim: 
SVR (dyocv..cm-3) 
Gmup A 
Group 3 
LVSP Imm Hgl 
Gmup A 
Group B 
MAP [mm HgJ 
Group A 
Groug 3 
CO Ililerrlminl 
Griwp A 
Group A 
Group B 
HR ibeaelmini 
Group A 
Group B 
LV peak dPldt positive (mm Hg,r 
Group A 
Gmup B 
VceKl @-‘I 
Group A 
thup 3 
“max I;-‘, 
Group A 
Grmm B 
LVEDP (mm Hg) 
Group A 
Group B 
MAPAP (mm Hgl 
Group A 
Group B 
PVR (mm Hg) 
Group A 
Group B 
1,121 f 136 
1,267 t 106 
137 + 5.5 
13, t 7.2 
107 * 3.2 
103 z 4.4 
6.7 + II.6 
6.2 e 0.4 
44k3.8 
36 f 2.8 
58 i 4.9t 
40 + 3.7 
8, ts 
F.9 I 5 
I.619 f 112 
1.459 t 81 
34 * 2.8: 
28 * 1.5 
51 t 3.82 
42 + 2.1 
9r 1.6t 
15 : 2.6 
15 i- 1.0 
I8 c 2.9 
106 t 14 
IO L 1.4 I, 2 1.7 
13 f 2.4 I5 2 2.6 
16 * 1.3 17+14 
IY i 1.2 ,6X 1.7 
106 f 38 110 2 39 
156 * 43 IlO? 30 II5 ? 44 
‘p < 0.05 versus conlml. tp < 0.0s. Group A versus 8. Values are expressed ar mean value ? SEM. CO = cardiac output: dP/dt = first derivative of left 
venlricular prerrure: HR = bean rare: LV = left ventricular: LVEDP = kn venlricular end diastolic presmre; LVSP = Ich venlriculsr rysfolic pressure; 
MAP = mean aneriat prerrue; MPAP = nran pulmonary awry prerrurc: ?VR = pulmonary vascular raistancc. SI = s!rokc index: SVR = syslemic vascular 
resistance: SWI = stroke work index: VcelU = dPldllP ar P = 40 mm He: Vmax = dPidLQ cxlrapolsled lo P = 0 mm Hg I& pressure. 
129 3 4.8 
131 + 7.8 
K!d f 3.0 
IW + 5.3 
85 * 5 
91 ?5 
5, ” 4.3+ 
41 f 2.9 
82 1.2 
14 z 2.9 
IS * I.3 
16 z 1.9 
(test II) was carried out, identical to pacing test 1. During test considered significant. A Student t test for paired observa- 
11 311 variables were reassessed at similar time intervals as tions was used to compare measurements during pacingtests 
during TesI 1. Blood for diltiazem assay was collected before 1 and II within each group. Group differences in hemody- 
and al 5 and 15 min of infusion and at the end of test Il,jusi namic and metabolic meal, values before and during dil- 
before discontinukm of pacing. At the onset of each s~xss tiazem administration and before, during and atier both atrial 
test, patients received atrapine (0.5 mg intravcnouslyj to pacing stress tests were compared using a Student I test for 
ensure identical maximal pacing heart rates. unpaired observations. A two-tailed p value < 0.05 was 
Statistical analysis. In each group. measurements made considered significant. In a separate analysis, a linear regres- 
during diltiazem administration were compared with base- sion model was applied to inves&ate the difference betweeu 
line valw bcforc inksion by using an analysis of variance plasma levels of diltiazem and effect measures within each 
for repeated measbrzments. A two-tailed p value < 0.05 was group, whereas differences in diltiazem levels between both 
963 f 111* 
865 2 58* 
120 IS.1’ Ill z 4.3- 
124 z 7.9’ 118 t 6.5- 
98 f 1.4 93 t 3.81 
89 c 4.1’ 86 f 4.1’ 
8.0 f Il.*- 
7.9 ? O.6_ 
4T z 4 7’ 
46 + 3.c 
55 t 4.4 
4s 2 4.9 
86 t 5 85 r 5 
94 + 4 91 24 
I.694 f 139 I.676 2 127 
1.526 x 87 1.444 r 95 
36 I 2.7+ 33 * 1.R 
Mr 1.8 29 f 1.8 
92 t 4.0” 
88 2.4.9’ 
80 I 5 
86 f 4 
34 f 2.3t 
28 + 2.1 
55 + 2% 
43 r 3.3 
I2 + 1.4’ 
17 f 2.8 
I? t I.2 
19 f 1.5 
92 ? 1.0’ 
9, ? 4.1’ 
7.4 f 0.6. 
7.5 + 0.5. 
49 3 3.6 
44 t 3.3’ 
54 ? 4.9 
46 f 4.8 
77 t 5 
81 f4 
1.576 2 104 
I.345 t :oo 
,I t 3.7t 
27 + 2.0 
54 I 2.41 
43 f 2.9 
I2 2 1.4” 
I6 + 2.8 
I8 i I.2 
19 + 2.3 
groups were compared 
observations. 
with Student f It251 for unpaired 
Results 
Plasma dittiazem tevels, Plasma diltiazem levetr were 
comparable in groups A and B. with peak leve!r of 869 5 
152 &liter and 926 + I69 &liter. respecrively. at 5 min 
of diltiazem administration. gradually decreasing to 339 z 
152 diter and 432 5 103 &liter. respectively. at maximal 
pacing rates during test Il. There was no significant relation 
between individual plasma levels and percent changes in 
hemodynamic varizblss. 
Systemic bemodynamic changes during dittiazem adminb 
Iration in patienls with normal verws impaired bawlire left 
ventricular fraction (Table It. Diluazem reduced svstemic 
vascular resistance equally in both groups (27% group A and 
32% group B, both p < O.Oj vs. control). re?ultiog in 
significant. similar decreases in left ventricular svstoiic ares- 
sure (15% group A and 14% group 6) and in mean artcnal 
pressure (13% group A and !7% group 3). Pressure changes 
occurred gradually, starting at ‘1 min of dittiazem edminis- 
tration but persisted until the end of tnc study. Canintc 
output improved significantly and consistently both. group 
A (19%) and in group B 127%). In contrast, stroke innex was 
increased only temporarily. immediately after the bolus 
infusion, in group A. whereas it remained elevated for the 
full duration of dittiaaem administration in group B (Fig. 2). 
Moreover, diltiazem induced a significantly greater percent 
increase in stroke index in group B than in group A patients 
(32 i 3% vs. 22 ? 7% respectively, p 4 11.01). 
Neither heart rate nor tsovolumetrlc indexes of contrac- 
tility changed in either group. Although the velocity vari- 
ables were already significantly reduced at baseline in pa- 
tients with impaired left ventricular function, they did not 
decline further during dittiazem administration. Also. 
whereas during the conlrol period left ventricular end- 
diastolic pressure was significantly elevated in group B 
compared with group A (15 2 2.6 mm Hg vs. 9 ? 1.6 mm Hg, 
respectively, p < 0.05). it did not increase further during 
dittiaaem administration in patients with impaired left vcn- 
tricular function. ln contrast, in group A patients. left 
ventricular filling pressure rose with 33% toward the end of 
the infusion period (p < 0.05 vs. control period). Pulmonary 
artery pressures and pulmonary vascular resistance did not 
change in either group. 
Coronury hemudynamic etTect.s of dittiazem in normal 
verse impaired basetine I& ventricular f nction (Table 3). 
Baseline values of coronary sinus blued flow and coronar: 
vascular resistance were significantly different in borh 
groups. However, subsequent changes during diltiazem in- 
fusion were similar, although short-lasting, occurring be- 
tween 5 and IO min of diltiazem infusion (Fig. 3:. Coronary 
flow increased by 26% and 17% and coronary vascular 
resistance decreased by 37% and 26% in group A and group 
B, respectively. Myocardial oxygen extraction (arterial and 
Figure 2. Systemic hemodynamic effects ofdiltiazembefwe pacing. 
Systemic vascular resistance WJR). left ventricularsyrtolic (LVSI’l 
and mean acrtic (MAP) pressure gradually decrease during diltiazem 
administration. Concomitantly, cardiac output (CO) improves. 
Changes are comparable in both gmtipr. IO contrast. the increase in 
stroke index (St) is more pronounced and persisted in patients with 
an impaired ventricular function (Gr B l!goup B. patienrs with an 
ejeclion fraction{efl~45%]). Values areexpressedas mean value + 
SEM. bt = beats; C = control; Gr = group; I = liter; ’ = minute. 
co:onary venous oxygen content difference) decreased only 
in group B (24% compared with baseline values, p i 0.05). 
The reduction in bath myocardial oxygen extraction and 
coronary vascular resistance persisted for the entire infusion 
period in group B. 
Systemic mad curwary hermudynamic effects &di!tiazem on 
hemodynamics during pacing (Tables 4 and 5). Baseline and 
maximal pacing heart rates were similar during atria1 pacing 
tests I and II in both wuns. In contrast. the rate-nrcssurc 
product, an index of myocardial oxygen demand, &as sig- 
uificantly reduced during test II, compared with test I (by 
26% inaroup Aand l%in xroupB). Meanarterial pressures 
increased significantly during !est I (by 14% in gmup A and 
II% in group 9). During test II, arterial pressures again 
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Table 3. Coronary Hemodynamic Changes Durirs Dilfiazem Infusion in Patients With Normal Versus Impaired Left 
Venlncular F~mclion 
Cuntrul Period 
CSBF imllminl 
CrouP .4 
Minuler Aircr Onw of Dilliarem Infudon 
116+9: 
175 I20 
0x7 ? 0.07:+ 
OS8 t o.cf,* 
6.08 + 0.X 
5.52 t 0.:9. 
7.52 t 0.74 
9.43 t I.SO 
9.64 f 0.60 
IS 
114 t 13 
170 t 18 
0 84 I 0.10 
0.56 f 0.06” 
595 i 052 
5.38 + 8.35’ 
7.99 z 0.97 
B.zu k I .I8 
9.07 i 0.w 
croup B 1o.m t I.21 9.88 t 1.30 9.43 f 1.5 8.73 f l.lO’ S,83 f I.09 9.20 t 1.28’ 
*p < 0.05 wrsu~ control. :p < 0.05. Gmup A wws Group B. CSBF = coronary sinus blood flow: CVR = coronary vawlar resistance: ul A - CS 0,eon. 
lent = diiknce in anerial and coronary 6i~tus oxygen conlenl: HR = heart fale: LVSP = left venlricular sydolic prcarurc; MVOl = myotardial oxygen 
connumplion; RPP = rdle-p*wurr prcdwt. VYlue5 we eipreised as mean value f SEM. 
increased in group A (by 12%, P < 0.05 vs. the control period) 
but not in group B. Also. changes in isovolumetric indexes of 
contractilhy during pacing before and aRer dihiazew were 
dlffcrent in both groups. in group 9, velocity indexes in- 
creased more during pacing after diltiazem than during the 
first pacing test before treatment (43 + 3 5-I [test 11 vs. 51 L 
3 a-’ [test llj, p < 0.05). In group A, however, contraclility 
indexes did not improve furtherduring test II after diltiazem. 
Moreover, in group B, coronary Bow increased less during 
pacing after dikiazem than during test 1 (241 2 24 mlimir: 
[test II vs. 210 i 20 ml/min [test Ill, p < O.OSl. Again, in 
group A, changes in coronary flow wcr: similar during both 
pacing tests. Myocardial oxygen extraction was significantly 
greater during test II than during test I in group B. 
AnfGschemic properties of diltiazem in patients with nor- 
mal WPSUG impaired teft venlricular function. During test II, 
10 patients in each group had no or less angina. compared 
with that in the first pacing leit before diltiazem administra- 
tion. Also, ST segment depression was significantly less in 
each group during test II than during test I (Fig. 4). In 
contrast, the effect of diltiazem on metabolic signs of isch- 
emia differed in both groups During test 1, a comparable 
change from myocardial lactate extraction at baseline to 
production was observed in groups A and B. However, 
during test 11, no such changes occurred in group B. In 
contrast, lactate production was again observed in group A, 
indicating a normalization of lactate metabolism in patients 
with impaired, but not in those with normal ventricular 
funaion (lactate extraction I5 s after pacing: -6 * 12% 
[group Al vs. 7 -t 5% [group El, p 4 0.05, Fig. 5). Moreover, 
in group B, the increase in left ventricular end-diastolic 
pressure, measured at 10 s after pacing. was 16 mm Hg less 
during test II than during test I. compared with adifference 
of I I mm Hg in group A (Fig. 6). 
Adverse eUccts. No untoward clinical effecis were ob- 
served. Myocardial ischemia did not occur during dihiazem 
administration before pacing. Only onc patient reported a 
short period of facial flushing. 
Discussion 
Syslemic hemodynamic effects of high dase intravenous 
dliiazem in impsired verse normal ventrkular function. In 
the present study, diltiazem administered at a high infusion 
rate was hemodynamically well tolerated by patients with 
impaired or preserved ventricular function. In both groups it 
induced comparable reductions in systemic vascular resis- 
tance and left ventricular systolic and aortic pressures ac- 
companied by an increase in cardiac output. Because other 
systemic hemodynamic variables did not change, at least not 
during the initial phase of the study, thia improvement of 
ventricular pump function most likely resulted from the 
systemic vasodilating effects of diltiazem and subsequent 
unloading of the left vcntriclc. However, the augmentation 
of left ventricular pump function appeared to be more 
pronounced in patients with impaired left ventricular func- 
tion at baseline. In the latter group, the increase in stroke 
index was signilicantly greater and longer lasting than in 
patients with wrmal len ventricular function. 
This observation is not surprising in rhe absence of other 
hcmodynamic changes. Comparable reductions in left yen- 
tricular systolic pressure with dihiazem are likely to induce 
a greater effect on systolic wall stress in patients with a 
dilated, nonhypertrophied left ventricle (group B in this 
REMME !zr AL. 715 
HIGH DOSE DlLTl~Zi3.l IN IYPAIRED VENTRICULAR FUNCllON 
gfoups diltiazem equally reduces coronary vascular resistance 
(CVR) and improves C@:WYV flow KSBFI. In contrast. mvocardi,l 
oxygen extra&w! !nrterial and coronary venous on& ccnlenl 
difference [A A-CS 9 contl) only decreases ingroup B despns equal 
redactions in the rate-pressure (double) producl (DP). an index of 
myocardial oxygen demand. Values arc expressed as mean value 2 
SEM. YVQ, = myocardial oxygen consumption; HR = heart rate; 
other abbreviations as in Figure 2. 
study) thao in patients with a normal-sized left ventricle 
(group A). Besides, although myocardial ischemia was net 
apparent before diltiazem administration. the subsequent 
greater reduction in myocardial oxygen demand in patients 
with au enlarged letl ventricle (group 8) may hx<e added ID 
the greater improvement of left veotriculat function in this 
group. An impmvement in cardiac or stroke volume index, 
orboth, has been repo~ttid by others in patients with nom4 
ventricular ftmction (4.6,10.211. Whereas unloading of the 
lef! ventricle .dth or without reflex cardiac slimulation has 
been suggested as the most likely causative factor, Dash et 
al. ($I) observed that regional left ventricular systolic im- 
provement after diltiazem occurred primarily in areas sup- 
plied by stenotic coronvy arteries that were hypokinetic at 
rest, suggesting that mechanisms resulting in relief of isch- 
emia mav be involved. Auementation of cardiac oerfor- 
mance after intravenous adn&istration of diltiazem has been 
reported in patients with congestive heart failure (19,22). 
The present study is the first to report an augmentation in 
cardiac petformance in patier ts with asymptomatic ventric- 
u!ai dysfuncuon. 
Ln vitro. the intrinsic cardiovascular properties of dil- 
tiazem, Including a negative inotropi; and chronotmpic 
eff~c;. are dose related (17.18). Despite the relatively high 
dose used in our study, neither heart rate nor contractility 
indexes decreased during diltiazem administration in either 
group. This lack of negative inotropic and chronotropic 
ekcts presumably reRcctr art interaction b:twecn the intrin- 
sic hemodynamic properties of diltiarem on the one hand 
and barorecepror-dependent reflex mechanisms on the 
other. This balance between primary and secondary cardio- 
vascular effects, well known for vaswxtive compwnds such 
as Cahum antagonists. not only depends on the pharmace 
lo$c profile of these agents, that is. the magnitude of 
vasodilator versus negative chronotropic and inotropic ac- 
tivity. but also ita dosage and method of administration. 
Thu,. in patients with coronarv arterv disease and normal 
left ventricular function at baseline. the second-generation 
dihydropyridine derivatives such as nisuldipine, oicardipine 
and isrddipine may result in a scccndary increase in heart 
rate and contractility. even in the presence of beta-blocking 
theraov IS-251. In contrast. with intravenous veraoamil. 
heart’nte usually dces not change. whereas contractility 
remains unaltered or is slightly depressed (26,27). Doses of 
intravenous diltiazem lower than those used in the present 
study induce fewer vawdilating effects and either reduce 
heart rate or do not change it (4,6-9.28); moreover. contrac- 
tility remains unaltered or may even diminish (8.29). The 
high dose infusion used in this study apparently evoked 
sufficient baroreceptor-depeodent sympathetic stimulation 
to counteract its intrinsic negative chronotropic and inotro- 
ps effects in both study groups. Even so, in patients with 
normal ventricular function at baseline, left vcatticular end- 
diastolic pressure increased significantly toward the end of 
diltiazem adminislration. In contrast, Ien ventricular filling 
pressures remained unaltered and even tended to improve in 
patients with impaired left ventricular function. Why this 
difference exists is not entirely clea?. 
A direct effect on diastolic behavior of the left veohicle is 
unlikely because the compound does not change the end- 
diastolic pressure-volume relation (21.29). Theoretically. 
myocardial ischemia. resulting fmm a preferential increase 
in caronay flow in normal coronary arteries and suhse- 
quently a steal phenomenon. may result in the observed 
change in left ventricular filling pressure. However, no 
patient showed signs or symptoms of ischemia during dil- 
tjazem administration and the changes in coronary flow were 
comparable in both groups. Another explanation for the 
observed difference in effect on end-diastolic pressures by 
diitiazem may be that the drug still has some negative 
inotropic effect. insufficiently appreciated by measuring 
pressure-derived velocity variables only. The subsequent 
increase in left ventricular filling pressure would be apparent 
only in patients with a normal-sized heart but would be 
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counteracted in enlarged ventricles by the greater reduction 
in wall stress after diltiazem. 
Diltiazem induced comparable improvcmenth in coronary 
Aow in both patient groups. We (3) have already reported 
this increase in coronary flow in a study wing dosages 
equivalent to those in the present study. The increase 
is short-lasting. observed only during and for 5 min after 
the holus infusion at a time that plasma dihiazem levels 
arc high. In contrast, significant effects on coronary Bow 
generally have not been observed with administration of 
lower doses (3,5,6,8-12.30). Myocardial oxygen extraction 
decreased in the prcscnt study. but only in patients with 
impaired left ventricular function. This effect was still 
present at the end of dihiazem administration when cor- 
onary flow had already normalized. This finding suggests 
that it was predominantly dependent on changes in myo- 
cardial oxygen demand and underlines the more pronounced 
effect on systolic wall stress in patients with impaired 
ventricular function. 
Hemodynrontc and sntl.ischemie elkts nf dilliuem during 
pacing. During pacing. diltiazem significantly decreased the 
rate-pressure product-and. hence, myocardial oxygen de- 
mand-in both study groups. Because it did not further 
improve coronary Row over and above the changes observed 
during the first pacing test, it is likely that its anti-ischemic 
effects are related to its systemic vasodilating properties. 
Whereas changes in the rate-pressure product were compa- 
rable in both groups, those in coronary Row were not. In 
patients with impaired left ventricular function. the increase 
in coronary flow during pacing after diltiazem administration 
was less than that during the pacing test before treatment. In 
addition. myocardial oxygen extraction decreased less dur- 
CSW (mllminl 
I”., r 0.6 
Y.? t 0.7 
126 I 10 
116r9 
Y.7 f u.4 
9.4 I 0.4 
19.4 5 3.5 
14.5 t 3.5 
ll.8~0.8’ 
11.g -r 0.S’ 
ing pacing after diltiazem. This finding suggests that in 
patients with impaired ventricular function and a relatively 
large heart. myocardial oxygen demand decreased to a 
greater extent as a result of systemic vasodilatian and 
ventricular unloading than in patient!, with normal function 
and a normal-sized ventricle. Theoretically. this could lead 
to more pronounced anti-ischemic effects of diltiazem in 
patients with impaired ventricular function at baseline. 
Although a clear anti-ischemic effect was present in both 
groups, as suggested by the reduction in ST segment depres- 
sion, differential changes in several metabolic and hemody- 
namic variables during pacing suggest that high dose dilt- 
kern may indeed reduce myocardial ischemia to a greater 
extent in patients with asymptomatic ventricular dysfunc- 
Zion. First. lactate metaboiism, which indiiatcd comparable. 
ischemia-induced anaerobic glycdysis during the pacing test 
before treatment in both groups, rcrr_Y .:d unchanged and 
nor,nal in patients with ventricular dysfunction during pac- 
ing after dilriazem. In contrast, lactate production recurred 
in patients with a normal-sized ventricle. Preliminary data 
indicale that lactate production. besides being an early 
marker of &hernia (20). has a better sensitivity and speci- 
ficity rhan those of commonly used variables. such as 
angina. ST segment changes or left venhicular filling pres- 
sure in our model of pacing-induced ischemia (31). Also, the 
increase is left ventricular end-diastolic pressure immedi- 
ately after pacing appeared less FtVnoUnCCd during pacing 
with diltiarem in patients with impaired versus normal left 
Plgure 4. ST segment changes during atrial (AP) pacing before and 
affer diltiarem in gmup A (halched bars) and gmap Et (open bars). 
Values are expressed as mean value -L SEM. APST = atrial pacing 
wess test; c= controf. 
ventricular function. Moreover, despite similar changes in 
left ventricular pressures during pacing with diltiazem in 
both groups, contractility indexes improved in patients with 
impaired but not in patients with a normal ventricular 
function at baseline. Furthermore. diltiazem prevented the 
(ischemia-induced) rise in arterial pressures observed during 
the fust pacing test in patients with impaired ventricuhu 
function, ttii not in patients with normal ventricular func- 
tion, during the second test. Pacing-induced myocardial 
ischamia is accompanied by systemic vasocoustriction and a 
rise in arterial pressures, al least under relatively severe 
ischemic conditions (32) and is possibly mediated by ele- 
vated sysk& norepinephrine and angiotensin II levels (33). 
Pharmacologic measures to reduce pacing-induced ischemia 
may prevent this (34), again suggesting that the anti-ischemic 
effect of high dose diltiazem possibly was more pronounced 
in patients with asymptomatic ventricular dysfunchon. 
Figure 5. Effect of diltiazem on myocardial lactate extraction during 
pacing. During atria1 pacing stress test (APST) I, comparable lactate 
production is found in group A (hatched bars) and group B @en 
bars). In coatrast, during test ii, lactate extraction is preserved in 
group B (value significantly different from value in test 1); however, 
lactate production values are reproducible during both tests iu group 
A. Values are exwersed as mean value i SEM. arl = arterial: 
art-ven = arterial’minus venous lactate; MAX = maximal pacing 
rates; p-p = post-pacing; other abbreviations as in Figure 4. 
LVEDP 
mmng 
+ P C.05 APST I “s APST II 
+ p <.DS Gr A YS B 
,1 t* *p<o5vsc 3 h 
20 
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i 
Figure 6. Effect of diltiazem on lefl ventricular end-diastolic pm- 
sure iR group A (batched bars) and group B (open bars). LVEDP = 
left ventricular end.diaHalic pressure: other abbreviations as in 
Figures 4 and 5. Values are expressed as mean value t SEM. 
Plasma diltiazem levels. Plasma diltiazem levels were 
comparable in both groups. Despite high initial values, 
hemodynamic deterioration was not observed in either pa- 
tient group and no untoward clinical effect or side effect was 
noted. As already observed in a previous study (7). plasma 
diltiazem levels did not correlate with hemodynamic 
changes. Moreover, levels assessed just before discontinua- 
tion of pacing were similar in both groups, suggesting that 
the difference in anti-ischemic effects of diltiazem is related 
to baseline cardiac condition t?:her than to differences in 
plasma diltiazem levels. 
Lbnitakms of the study. In the present study no placebo 
control group was studied because the purpose of the study 
was to compare the effect of diltiazem m patients with 
normal versus impaired left ventricular function rather than 
to evaluate whether the actions of diltiazem could be ex- 
plained by a placebo effect. Several reports confirm the 
reproducibility of metabolic, ECG and hemodynamic vari- 
ables of ischemia. such as those used by us W-37) and after 
much shorter pacing intervals than those in the present 
study. Moreover, in a comparison of placebo-treated inter- 
vals between incremental atrial pacing stress tests of 15 to 
60 min, we have observed good individual reproducibility of 
myxardial lactate production values after pacing int~xvals 
245 min (38). The overage pacing interval in the present 
study was well over M) min. In addition, the anti-ischemic 
effect of both high and low dose intravenous diltiazem has 
been confirmed in various studies using atrial pacing as 
stress (3.4.61. Because the main purpose of this study was to 
compare hemodynamic tolerability and anti-ischemic efi- 
cacy of high dose intravenous diltiazem in patients with 
different levels of cardiac function, we did not submit a 
relatively large patient group to lengthy invasive procedures 
under placebo conditions. 
Potential clinkal implications. This study indicates that 
high doses of intravenously administered diltiazem are safe 
and may improve cardiac pump function in patients with 
coronary artery disease. Although our study groups were 
smaii, our data suggest that lhe improvement in function was 
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better in patients with depressed than in those with normal coraaary hemody~msr dunng am4 pacmr II pawn!< wnh <tah!r. 
ventricular Funcrion at baseline. h4oreover. several mew *,cnlO”Jl q7J’“a- impllLalionr For mcchaniim of ac’1.a” Circuiarin” 
bolic and hemodynamic markers of ischemia icdicatc rhar 
i”xb::1’l!&53. 
13 V1”01110 C. ti1ordano 4. De Capno L. e, at. RqioMI COionary bawdy- 
the anti-ischtmic effects of diltiazem may he more pro- namic &eci* ofdilriazem in man. Am Hart i 19X3:116;7%%05. 
nounced in patients with such depressed function. This I-I. W&h&n R. ,Ashikawa K. 5ing RJ. E&I of diltrarem. a calcium 
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prolonged periods of ischemla at rest. In lhis situation. yhoiun emlkil compulcd b~magmpky and mdionuclide an$ognpky. 
the systemic vasodilating effects of dilriazem are important. Am J Canliul 19&3.61:1172-7. 
as they result in a red ction in myocardial oxygen demand 
16. K&b R41. Rusamond TL. Fox Uh. S&i BE. Bergnun SR. En- 
haccment of alvage of qerfustd istkrmx myocxdum by dikwem. 
and subsequently in ischemia. and hence may improbe J .krn roll Cxdiol IYX&B:86-71. 
ventricular function. In addition. the coronary vasodilating 17 blomd \1. rune L. Greenspan Ah!. Effect of dilrkem CHI cdlcium 
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result of ischemia. it seems worthwhile to further EVBIU- putenrial mrrhanisms. Am J Cardml 198?:494--506 
ate the clinical usefulness of high dose diltiazem in the 3. W&h RW. Poner C5. Stukng MR. O‘Rwrke RA. Beneficial hemody- nmw vlTcul\ olinlravenaur and onldilriazem B sercre~ons~rtrwkti 
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